Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease

por Bergqvist, Viktoria, Holmgren, Johanna, Klintman, Daniel, Marsal, Jan
Publicado 2022

Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease

por Andréasson, Kristofer, Alrawi, Zaid, Persson, Anita, Jönsson, Göran, Marsal, Jan
Publicado 2016

Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile

por Löfroos, Ann-Britt, Kadivar, Mohammad, Resic Lindehammer, Sabina, Marsal, Jan
Publicado 2017

Severe intestinal dysbiosis is prevalent in primary Sjögren’s syndrome and is associated with systemic disease activity

por Mandl, Thomas, Marsal, Jan, Olsson, Peter, Ohlsson, Bodil, Andréasson, Kristofer
Publicado 2017

Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study

por Andréasson, Kristofer, Neringer, Karl, Wuttge, Dirk M., Henrohn, Dan, Marsal, Jan, Hesselstrand, Roger
Publicado 2020

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

por Marsal, Jan, Barreiro-de Acosta, Manuel, Blumenstein, Irina, Cappello, Maria, Bazin, Thomas, Sebastian, Shaji
Publicado 2022

Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

por Bergqvist, Viktoria, Hertervig, Erik, Gedeon, Peter, Kopljar, Marija, Griph, Håkan, Kinhult, Sara, Carneiro, Ana, Marsal, Jan
Publicado 2017

Exocrine pancreatic function is preserved in systemic sclerosis

por Bozovic, Gracijela, Pullerits, Rille, Ståhl, Arne, Ydström, Kristina, Wenger, Daniel, Marsal, Jan, Thulin, Pontus, Andréasson, Kristofer
Publicado 2019

Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations

por Alyamani, Manar, Kadivar, Mohammad, Erjefält, Jonas, Johansson-Lindbom, Bengt, Duan, Rui-Dong, Nilsson, Åke, Marsal, Jan
Publicado 2023

A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT: a three-arm parallel blinded randomised controlled single-centr...

por Leander, Peter, Stathis, Georgios, Casal-Dujat, Lucia, Boman, Karolina, Adnerhill, Ingvar, Marsal, Jan, Böök, Olof, Fork, Thomas
Publicado 2022

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

por Fleisher, Mark, Marsal, Jan, Lee, Scott D., Frado, Laura E., Parian, Alyssa, Korelitz, Burton I., Feagan, Brian G.
Publicado 2018

Lung Mast Cells Have a High Constitutive Expression of Carboxypeptidase A3 mRNA That Is Independent from Granule-Stored CPA3

por Siddhuraj, Premkumar, Clausson, Carl-Magnus, Sanden, Caroline, Alyamani, Manar, Kadivar, Mohammad, Marsal, Jan, Wallengren, Joanna, Bjermer, Leif, Erjefält, Jonas S.
Publicado 2021

Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study

por Mårild, Karl, Söderling, Jonas, Stephansson, Olof, Axelrad, Jordan, Halfvarson, Jonas, Bröms, Gabriella, Marsal, Jan, Olén, Ola, Ludvigsson, Jonas F.
Publicado 2022

Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis

por Sagard, Jonas, Olofsson, Tor, Mogard, Elisabeth, Marsal, Jan, Andréasson, Kristofer, Geijer, Mats, Kristensen, Lars Erik, Lindqvist, Elisabet, Wallman, Johan K.
Publicado 2022

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease

por Bergqvist, Viktoria, Kadivar, Mohammad, Molin, Daniel, Angelison, Leif, Hammarlund, Per, Olin, Marie, Torp, Jörgen, Grip, Olof, Nilson, Stefan, Hertervig, Erik, Lillienau, Jan, Marsal, Jan
Publicado 2018

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

por Visuri, Isabella, Eriksson, Carl, Karlqvist, Sara, Lykiardopoulos, Byron, Karlén, Per, Grip, Olof, Söderman, Charlotte, Almer, Sven, Hertervig, Erik, Marsal, Jan, Malmgren, Carolina, Delin, Jenny, Strid, Hans, Sjöberg, Mats, Bergemalm, Daniel, Hjortswang, Henrik, Halfvarson, Jonas
Publicado 2023

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study

por Eriksson, Carl, Rundquist, Sara, Lykiardopoulos, Vyron, Udumyan, Ruzan, Karlén, Per, Grip, Olof, Söderman, Charlotte, Almer, Sven, Hertervig, Erik, Marsal, Jan, Gunnarsson, Jenny, Malmgren, Carolina, Delin, Jenny, Strid, Hans, Sjöberg, Mats, Öberg, David, Bergemalm, Daniel, Hjortswang, Henrik, Halfvarson, Jonas
Publicado 2021